Results 41 to 50 of about 70,663 (209)

Third-Generation Anti-CD47-Specific CAR-T Cells Effectively Kill Cancer Cells and Reduce the Genes Expression in Lung Cancer Cell Metastasis

Journal of Immunology Research, 2021
CD47 is a cell surface glycoprotein molecule, belonging to the immunoglobulin superfamily, binding to various proteins including integrins, thrombospondin-1, and signal regulatory protein α (SIRPα).
Huyen Thi La, Dao Bich Thi Tran, Hai Manh Tran, Linh Trong Nguyen   +3 more
doaj   +1 more source

Optimization of chimeric antigen receptor (CAR) therapy

, 2021
In this thesis, we focused on how to improve the safety and efficacy of CAR T cell therapy. First, we studied different safeguard mechanisms for CAR T cell depletion in case of short and long-term toxicities. Second, we explored strategies for reducing a priori the risk of severe side effects upon CAR T cell administration through the generation of ...
openaire   +2 more sources

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy

Frontiers in Immunology, 2023
Advancements in chimeric antigen receptor engineered T-cell (CAR-T) therapy have revolutionized treatment for several cancer types over the past decade. Despite this success, obstacles including the high price tag, manufacturing complexity, and treatment-
Marisa K. Kilgour, Donald J. Bastin, Seung-Hwan Lee, Seung-Hwan Lee, Michele Ardolino, Michele Ardolino, Michele Ardolino, Scott McComb, Scott McComb, Scott McComb, Alissa Visram   +10 more
doaj   +1 more source

NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development [PDF]

Cells, 2021
In recent years, cell-based immunotherapies have demonstrated promising results in the treatment of cancer. Chimeric antigen receptors (CARs) arm effector cells with a weapon for targeting tumor antigens, licensing engineered cells to recognize and kill cancer cells.
Ali Bashiri Dezfouli, Mina Yazdi, Alan Graham Pockley, Mohammad Khosravi, Sebastian Kobold, Ernst Wagner, Gabriele Multhoff   +6 more
openaire   +5 more sources

A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers

Nature Communications, 2022
Antigen escape represents a potential drawback of chimeric antigen receptor T cell (CAR-T) therapy targeting a single tumor-associated antigen. To reduce the risk of antigen escape, here the authors report the design and characterization of a BAFF ligand
Derek P. Wong, Nand K. Roy, Keman Zhang, Anusha Anukanth, Abhishek Asthana, Nicole J. Shirkey-Son, Samantha Dunmire, Bryan J. Jones, Walker S. Lahr, Beau R. Webber, Branden S. Moriarity, Paolo Caimi, Reshmi Parameswaran   +12 more
doaj   +1 more source

A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy [PDF]

, 2017
Adoptive cell therapy using chimeric antigen receptor (CAR)-engineered T cells has emerged as a very promising approach to combating cancer. Despite its ability to eliminate tumors shown in some clinical trials, CAR-T cell therapy involves some ...
Erhao Zhang, Hanmei Xu
core   +2 more sources

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy [PDF]

, 2020
Chimeric antigen receptor (CAR) T-cell therapy has produced remarkable anti-tumor responses in patients with B-cell malignancies. However, clonal kinetics and transcriptional programs that regulate the fate of CAR-T cells after infusion remain poorly ...
Adair, Jennifer E., DeBerg, Hannah A., Enstrom, Mark R., Gersuk, Vivian, Gottardo, Raphaël, Hanafi, Laïla-Aïcha, Hawkins, Reed, Kiem, Hans-Peter, Linsley, Peter S., Maloney, David G., Pande, Dnyanada, Riddell, Stanley R., Sheih, Alyssa, Turtle, Cameron J., Voillet, Valentin, Wohlfahrt, Martin E., Yajima, Masanao   +16 more
core   +1 more source

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. [PDF]

, 2017
INTRODUCTION: Colorectal cancer remains the second leading cause of cancer death in the United States, and new strategies to prevent, detect, and treat the disease are needed.
Aka, Allison A., Pattison, Amanda M., Rappaport, Jeff A., Sato, Takami, Snook, Adam E., Waldman, Scott A.   +5 more
core   +2 more sources

Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies [PDF]

Journal of Thoracic Oncology, 2018
Chimeric antigen receptor (CAR) T cells are patient T cells that are transduced with genetically engineered synthetic receptors to target a cancer cell surface antigen. The remarkable clinical response rates achieved by adoptive transfer of T cells that target CD19 in patients with leukemia and lymphoma have led to a growing number of clinical trials ...
Stefan Kiesgen, Leonardo Chicaybam, Navin K. Chintala, Prasad S. Adusumilli   +3 more
openaire   +2 more sources

Circumventing antivector immunity: potential use of nonhuman adenoviral vectors [PDF]

, 2014
Adenoviruses are efficient gene delivery vectors based on their ability to transduce a wide variety of cell types and drive high-level transient transgene expression. While there have been advances in modifying human adenoviral (HAdV) vectors to increase
Beard C.W., Benkö M., Cauthen A.N., Crawford-Miksza L., Estrella Lopez-Gordo, Gall J., Gall J.G., Gattoni A., Ginsberg H.S., Haviv Y.S., Hofmann C., Iva I. Podgorski, Kajon A.E., Kanerva A., Kass-Eisler A., Kuriyama S., Mastrangeli A., Michou A.I., Nicholas Downes, Ramon Alemany, Rogozhin V.N., Roy S., Seiradake E., Shmarov M.M., Soudais C., Tutykhina I.L., Wang D.Y., Wohlfart C., Ying B., Zakhartchouk A.N., Zeng Q.   +30 more
core   +3 more sources